Tuesday broker round-up UPDATE
26th Nov 2013 08:18
BBA Aviation: Goldman Sachs shifts target price from 420p to 425p and reiterates a buy recommendation. BTG: Numis raises target price from 350p to 440p upgrading from reduce to hold. Cambria Automobiles: Panmure Gordon starts with a target price of 61p and a buy recommendation. Daily Mail & Gener
Read moreFriday broker round-up UPDATE
15th Nov 2013 07:38
Amlin: Berenberg raises target price from 398p to 434p, but still recommends selling. Barclays cuts target price from 481p to 453p and retains an overweight rating. Antofagasta: Numis raises target price from 750p to 850p and reiterates a hold recommendation. AstraZeneca: Liberum Capital upgrades
Read moreFTSE 250 movers: Oxford Instruments leaps on Andor Tech talks
12th Nov 2013 15:15
Oxford Instruments surged after "significant strengthening" in its second-quarter results as it revealed it was in talks to acquire AIM-listed Andor Technology. Shares in TalkTalk leapt after the company upped its dividend for the first half and raised its full-year guidance. The group said it expe
Read moreBTG H1 results broadly in-line, sees larger end-market potential
12th Nov 2013 11:10
- H1 revenues in line with consensus forecasts - EPS up 21 per cent to 6.8p - Guidance for Varisolve raised Healthcare group BTG drove first half revenues higher against tough comparators, as recent acquisitions made immediate contributions. The FTSE 250 group lifted underlying revenues 17% to £1
Read moreTuesday broker round-up UPDATE
12th Nov 2013 09:20
Accesso: Canaccord Genuity raises target price from 680p to 770p and keeps a buy recommendation. Andor Technology: FinnCap places both its target price (prev.: 390p) and its hold recommendation under review. Babcock International: Jefferies increases target price from 1250p to 1600p retaining a bu
Read moreSunday share tips: TalkTalk, Fyffes, Halfords
10th Nov 2013 16:28
TalkTalk's focus on the cheap end of the pay-TV market is a winning formula, the Sunday Times's Danny Fortson wrote in his Inside the City column. When it reports half-year results on November 12th analysts will be looking out for how its new ultra-budget Essentials package has performed. Barclays e
Read moreSector movers: Shire gives pharma sector a boost after Q3 beat
24th Oct 2013 15:31
Strong results from Shire injected some gains into the pharmaceuticals sector on Thursday after the company beat quarterly forecasts and hiked its guidance for the full year. The FTSE 100 specialty biopharmaceuticals stock was up an impressive 8.4% at 2,737p in afternoon trade following its results
Read moreBTG lifts full-year guidance, boosted by acquisitions
3rd Oct 2013 07:46
Healthcare company BTG lifted its full-year revenue expectations following the strong performance of newly acquired businesses. The group said it has made good progress on integrating the Targeted Therapies division of Nordion Inc. and EKOS Corporation - which were purchased in July at a combined
Read moreBTG welcomes marketing approval of MS treatment
18th Sep 2013 08:17
Specialist healthcare company BTG, which receives an undisclosed royalty on all sales of multiple sclerosis treatment Lemtrada, said Wednesday that the European Commission had approved the product for marketing. The official announcement was made the previous day by Sanofi and its subsidiary Genzy
Read moreTuesday broker round-up UPDATE
17th Sep 2013 08:56
Aggreko: Credit Suisse reduces target price from 2000p to 1400p and downgrades from neutral to underperform. Antofagasta: WH Ireland downgrades to neutral. Associated British Food: Nomura moves target price from 1650p to 1670p staying with its reduce rating. Aviva: Berenberg downgrades from hold
Read moreBTG sells brachytherapy business to Eckert & Ziegler
17th Sep 2013 07:36
Healthcare company BTG is selling its brachytherapy business to Germany's Eckert & Ziegler Group after receiving a warning letter from the Food and Drug Administration (FDA). In May the firm stopped the manufacture and distribution of the brachytherapy products following a letter from the FDA which
Read moreBBA Aviation CEO sells 85,000 shares
16th Sep 2013 16:28
BBA Aviation Chief Executive, Simon Pryce, on Friday traded in 85,000 shares, reducing his stake in the FTSE 100 group to 989,720. Pryce sold the shares at 321.26p each, pocketing £273,070. The transaction was made less than a week after the company said talks had ended with Dubai Aerospace Enter
Read moreFriday broker round-up UPDATE
6th Sep 2013 08:01
Antofagasta: Canaccord Genuity lowers target price from 1035p to 1020p, while leaving its buy recommendation unchanged. Ashmore Group: Canaccord Genuity downgrades from buy to hold with a target price of 380p. Associated British Foods: Societe Generale upgrades to hold with a target price of 1900p
Read moreBTG trading in line after acquisitions
16th Jul 2013 07:44
Specialist healthcare company BTG said it has been trading in line with expectations with strong operational progress. In a trading update for the period from April 1st to July 15th, the group re-iterated a full-year guidance of revenues in the range of £235m to £245m. During the period, the compa
Read moreTuesday broker round-up UPDATE
11th Jun 2013 07:22
AG Barr: Investec cuts target price from 591p to 581p, while upgrading from add to buy. Canaccord Genuity upgrades to buy with its target price at 570p. Aquarius Platinum: Nomura reduces target price from 90p to 65p, but keeps its buy recommendation. AstraZeneca: Berenberg takes target price from
Read more